Metoprolol Administration Guidelines

Cardiovascular Indications

The American Heart Association recommends metoprolol administration for hypertension, angina pectoris, myocardial infarction, supraventricular tachycardia, and heart failure, with specific dosing protocols and contraindications for each condition 1, 2
Initial dosing of metoprolol tartrate is 25-50 mg twice daily, with metoprolol succinate (extended-release) at 50-200 mg once daily, as recommended by the American College of Cardiology 2
Maximum dose is 200 mg daily for metoprolol tartrate and 400 mg daily for metoprolol succinate, according to the American College of Cardiology 2
Target blood pressure reduction should be at least 20/10 mmHg, ideally to 140/90 mmHg, as suggested by the American College of Cardiology 2
For supraventricular tachycardia, metoprolol can be administered IV at 5 mg over 1-2 minutes, repeated as required every 5 minutes to maximum dose of 15 mg, as recommended by the American Heart Association 1, 2

The American College of Cardiology states that absolute contraindications for metoprolol administration include signs of heart failure or cardiogenic shock, low output state, PR interval greater than 0.24 seconds, second or third-degree heart block without a functioning pacemaker, and active asthma or reactive airways disease 4, 5
Risk factors for cardiogenic shock include age greater than 70 years, systolic blood pressure less than 120 mm Hg, sinus tachycardia greater than 110 bpm or heart rate less than 60 bpm, and increased time since symptom onset, as identified by the American College of Cardiology 4

The American College of Cardiology recommends monitoring blood pressure, heart rate, and ECG during IV administration, and targeting a resting heart rate of 50-60 beats per minute unless limiting side effects occur 5
Monitoring for signs of worsening heart failure or bronchospasm, particularly during initiation, is also recommended by the American College of Cardiology 2

Early IV beta-blockers in STEMI showed neutral effect on combined endpoint of death, recurrent MI, or cardiac arrest in the COMMIT trial, as reported by the American Heart Association 3
While IV beta-blockers reduced recurrent MI and ventricular fibrillation, they increased risk of cardiogenic shock, especially in the first 24 hours, according to the American College of Cardiology 3, 4
For patients with acute heart failure, beta-blockers should be used cautiously when more than basal pulmonary rales are present, as suggested by the European Society of Cardiology 6
In patients with AMI who stabilize after developing acute heart failure, beta-blockers should be initiated early, as recommended by the European Society of Cardiology 6
For chronic heart failure patients, initiate beta-blockers only after stabilization (usually after 4 days), as suggested by the European Society of Cardiology 6
Avoid abrupt cessation of therapy to prevent rebound hypertension or worsening of angina, as recommended by the American College of Cardiology 2